Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...

CSL shares have dropped significantly in 2025, reaching a seven-year low, due to restructuring and downgraded growth prospects. The company’s core business is robust, with ongoing global demand and ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults ...

Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, and internationally. It operates ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Dr Brian McNamee AO has executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. He also has global perspective and understanding of ...

CSL Limited (CSL), an ASX-listed company, is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.

About DuPont de Nemours Inc. DuPont de Nemours, Inc. is a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the ...